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Abstract
Summary This study aimed to determine the interaction between baseline FRAX® fracture probability and romosozumab
efficacy. Using an ITT approach, it was determined that the efficacy of romosozumab on clinical fracture, osteoporotic fracture,
and major osteoporotic fracture is significantly greater in patients at high baseline fracture risk, when compared with placebo.
Introduction Post hoc analyses of placebo-controlled osteoporosis treatment studies have shown significantly greater reductions
of fracture incidence for higher fracture risk patients. This study determined the interaction between baseline FRAX® fracture
probability and romosozumab efficacy in the placebo-controlled first year of the phase 3 FRAME study (NCT01575834).
Methods Using an ITT approach, an extension of Poisson regression analysis studied the relationship between treatment,
FRAX® 10-year probability of major osteoporotic fracture (MOF, calculated without BMD) and risk of first incident fracture
(adjusting for age and follow-up time). Treatment interactions considered outcomes of all clinical fractures, osteoporotic frac-
tures, MOF, clinical vertebral fractures, and morphometric vertebral fractures. Two-sided p value of < 0.1 for the interaction
between treatment and FRAX® was considered significant.
Results Compared with placebo, romosozumab reduced the incidence of all fracture outcomes in the first year (range: 32%
reduction in MOF [p = 0.07] to 80% reduction in clinical vertebral fractures [p = 0.038]). Significant interactions were observed
between efficacy and baseline FRAX® probability for composite outcomes of clinical fractures, osteoporotic fractures, and MOF
(p = 0.064–0.084), but not vertebral fractures (p > 0.3). For example, romosozumab decreased all clinical fractures by 22% at the
25th centile of FRAX® probability but the reduction was 41% at the 75th centile. Exclusion of vertebral fractures from each
composite fracture outcome (i.e. only nonvertebral fractures included) showed even stronger interactions with baseline FRAX®
probability (p = 0.036–0.046).
Conclusions Efficacy of romosozumab on clinical fracture, osteoporotic fracture, and MOF is significantly greater in patients at
high baseline fracture risk compared with placebo.
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Romosozumab, a monoclonal antibody that binds and inhibits
sclerostin (a negative regulator of bone formation secreted by
osteocytes), has a dual effect of increasing bone formation and
decreasing bone resorption [1, 2]. In two large phase 3 clinical
trials, romosozumab has proved superior to placebo and oral
alendronate in its ability to reduce fractures [3–6]. In the
FRAME study (NCT01575834), a pivotal fracture study in
postmenopausal women with osteoporosis, a year of
romosozumab, 210mg subcutaneously (s.c.) monthly, follow-
ed by a year of denosumab (60 mg s.c. every 6 months) was
compared to a year of placebo monthly injections followed by
a year of denosumab [3]. The romosozumab arm showed a
73% lower relative risk of vertebral fractures and a 36% lower
risk of clinical fractures, by the 1-year time point, comparable
to the 75% and 33% lower relative risk in the respective out-
comes by the 2-year time point. Post hoc subgroup analyses
from FRAME have suggested that greater efficacy might oc-
cur in high-risk patients [7].
Several analyses in a number of placebo-controlled studies
have explored the interaction between treatment efficacy and
baseline fracture risk characterised using the FRAX® tool
[8–15]. This approach avoids the limitations of subgroup anal-
yses by seeking to determine if there is a significant interaction
between efficacy and fracture risk, with the latter handled as a
continuous variable. Evidence that the efficacy of some inter-
ventions is greater in patients with higher baseline FRAX®
fracture probabilities has been reported for clodronate [9],
bazedoxifene [8], and denosumab [13], but not for other
agents such as raloxifene [10], strontium ranelate [11],
teriparatide [14], and abaloparatide [16]. We wished to test
the clinical hypothesis that there would be an interaction be-
tween the efficacy of romosozumab and fracture probabilities
assessed at study entry. Given the design of the romosozumab
trials described above, the analysis was confined to the first
year of the FRAME study.
Methods
In this independent post hoc analysis of the phase 3 FRAME
trial, we used prospectively collected baseline FRAX® risk
variables to evaluate the efficacy of romosozumab on fracture
outcomes as a continuous function of baseline fracture
probability.
Details of the FRAME study are published elsewhere [3].
Briefly, in this international, double-blind, placebo-controlled,
parallel group trial, women with postmenopausal osteoporosis
were randomly assigned to receive romosozumab in a blinded
fashion, at a dose of 210 mg, or placebo. Randomization was
stratified according to age (< 75 years vs. ≥ 75 years) and
prevalent vertebral fracture (yes vs. no). Romosozumab or
placebo was administered s.c once monthly for 12 months,
followed by open-label denosumab (Prolia, Amgen), at a dose
of 60 mg which was administered s.c every 6 months for an
additional 12 months. A total of 7108 women between the
ages of 55 and 90 years with a BMD T-score less than − 2.5
but at least − 4.0 at the lumbar spine or total hip were studied;
all received daily supplements containing at least 1000 mg of
calcium daily with vitamin D (400 to 800 IU daily). Fully
anonymised, individual level study data were provided by
Amgen to the Centre for Metabolic Bone Diseases,
University of Sheffield.
Baseline FRAX® probabilities
Ten-year fracture probability was assessed with the FRAX®
tool (version 3.11) in all women at baseline. In brief, clinical
risk factors were used to estimate 10-year probability of a
major osteoporotic fracture (MOF: hip, clinical spine, fore-
arm, or humerus fracture) or of a hip fracture alone [17]. The
fracture probability can be calculated with clinical risk factors
alone, or with femoral neck BMD included. The clinical risk
factors comprised sex, age, body mass index (BMI), and
dichotomised risk variables documenting a prior fragility frac-
ture, parental history of hip fracture, current tobacco smoking,
ever long-term use of oral glucocorticoids, rheumatoid arthri-
tis, other causes of secondary osteoporosis, and alcohol con-
sumption of 3 or more units daily.
For the purposes of this analysis, a prior fragility fracture
excluded pathological fractures, any fractures arising before
the age of 18 years and fractures at sites not considered to be
osteoporotic (i.e. ankle, facial bones, fingers, foot, hand, knee
cap, knee, skull, and toes) [18]. One or more prevalent verte-
bral fractures (grades 1–3 on the Genant scale) on baseline
spine imaging were included as a prior fracture.
In addition to the dependence on clinical risk factors, frac-
ture probability varies markedly in different regions of the
world [19, 20] so that specific ethnic and country models were
used as appropriate. For two countries where FRAX® models
were not available (Dominican Republic and Latvia), appro-
priate surrogate models were used (Colombia and Estonia,
respectively).
Fracture outcomes
All incident fractures during the study follow-up were adjudi-
cated and confirmed via x-ray or radiology reports. Sites of
fracture, but not ICD codes, were provided and clinical frac-
ture outcomes, regardless of the level of trauma, were allocat-
ed to four categories: any clinical fracture (all fractures includ-
ing those of the feet, ankles, hands, face, and skull); any oste-
oporotic fracture (as any clinical fracture but excluding those
of the feet, ankles, hands, face, and skull); MOF; and hip
fracture. Incident vertebral fractures were documented either
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as a clinical vertebral fracture (identified in the presence of
back pain and usually requiring radiographic assessment out-
side of the prespecified schedule) or a morphometric vertebral
fracture. The latter were assumed to have occurred mid-way
between the date of the scheduled radiograph where the frac-
ture was found and the date of a previous scheduled radio-
graph, an assumption that does not impact materially on the
analysis of efficacy.
Statistical analysis
This was an intention-to-treat (ITT) analysis. A Poissonmodel
was used to study the relationship between age, the time since
baseline (months), treatment and calculated 10-year probabil-
ity of a major osteoporotic fracture, and their effects on the
risk of fracture with only the first of any particular fracture
outcome of interest being counted per patient [21, 22]. The
extended Poisson regression analysis can estimate effects that
vary in time, either linearly or nonlinearly, by studying the
interactions between the time in study and the variable of
interest (i.e. fracture risk). When there is no interaction with
time, this extended Poisson regression model gives results
very similar to a Cox regression model. Person-years were
used (in contrast to a linear logistic model). The hazard func-
tion for fracture was assumed to be:
exp(β0 + β1 current time from baseline + β2 current age +
β3 10-year probability + β4 treatment + β5 10- year probability
treatment).
The variable “10-year probability treatment” tests for an
interaction between efficacy and baseline 10-year probability
and was handled as a continuous variable by determining if β5
> 0. Treatment interactions considered the following fracture
outcomes: all clinical fractures, osteoporotic fractures, MOF,
clinical vertebral fractures, and morphometric vertebral frac-
tures. A further analysis considered the composite fracture
outcomes (e.g. any clinical fracture, osteoporotic fractures,
and MOF) with the exclusion of vertebral fractures, thus pro-
viding variable representing nonvertebral fractures.
The 10-year probability of a major osteoporotic fracture
without the inclusion of BMD was used as the base case in
the treatment interaction analyses. Interactions other than 10-
year probability treatment, such as BMD T-score treatment,
previous fracture treatment, and age treatment, were explored
in sensitivity analysis. A two-sided p value of 0.1 for the
interaction between treatment and FRAX® was considered
significant. Additional exploratory analyses included those
where hip fracture or nonvertebral fracture was the outcome
of interest; where FRAX®was calculated with the inclusion of
BMD; and finally, an examination of the effects on the any
fracture outcome comparing the Latin American region study
centres to the whole study population. The latter was
prompted by a post hoc analysis of FRAME that showed that
the risk of nonvertebral fracture in the region of Latin America
was higher in the romosozumab group than in the placebo
group, albeit not significantly (hazard ratio [HR] = 1.25;
95% confidence interval [CI], 0.68–2.27) [3, 7]. By contrast,
among the patients outside the region of Latin America,
romosozumab significantly decreased the incidence of
nonvertebral fracture (HR = 0.58; 95% CI, 0.37–0.89) [3, 7].
Hazard ratios for treatment effect and 95% CI were com-
puted as a continuous variable. For tabular presentation, HRs
are shown at the 10th, 25th, 50th, 75th, and 90th percentile of
fracture probability. In figures, the associations are shown as a
continuous function between the 1st and 99th percentiles ex-
cept where indicated.
Results
A summary description of the data used in this FRAX® anal-
ysis is provided in Table 1. Data on the clinical risk factors
used in FRAX®were available in 7163 (99.7%) of the women
included in FRAME. The mean probability of a major osteo-
porotic fracture was 9.7% and for a hip fracture was 3.9% for
the base case predictor of FRAX® calculated without BMD.
When BMD was used in the FRAX® calculation, the proba-
bilities tended to be greater than those based on clinical risk
factors alone, reflecting the need for a relatively low BMD as
an inclusion criterion for the trial.
During the first year of FRAME, a total of 178 (2.5%)
women sustained one or more clinical fractures, with
131(1.8%) and 89 (1.2%) experiencing at least one
Table 1 Summary description of the baseline data provided for




Age (years, mean ± SD) 70.9 ± 6.9
BMI (kg/m2, mean ± SD) 24.7 ± 4.4
Previous fracture (%, n) 18%, 1313
Parental hip fracture (%, n) 11%, 756
Current smoking (%, n) 10%, 745
Glucocorticoids (%, n) 0%, 13
Rheumatoid arthritis (%, n) 0%, 10
Secondary osteoporosis (%, n) 1%, 71
Alcohol 3 or more units per day (%, n) 1%, 70
Femoral neck BMD T-score (mean ± SD) − 2.80 ± 0.30
FRAX 10-year probabilities
Hip fracture (including BMD) (mean ± SD) 5.5 ± 5.0
Hip fracture (excluding BMD) (mean ± SD) 3.9 ± 4.6
MOF (including BMD) (mean ± SD) 12.5 ± 8.0
MOF (excluding BMD) (mean ± SD) 9.7 ± 7.2
BMD, bone mineral density; BMI, body mass index; MOF, major osteo-
porotic fracture; SD, standard deviation
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osteoporotic fracture or MOF, respectively. Seventy-five
(1.0%) women sustained one or more new morphometric ver-
tebral fractures, but only 12 (0.2%) sustained clinical vertebral
fractures; 22 (0.3%) women sustained a hip fracture.
Overall effects of treatment
The efficacy of romosozumab on fracture outcomes was ob-
served within the first year of the study when the treatment
was compared with placebo (Table 2). Romosozumab signif-
icantly decreased the risk of osteoporotic fracture, clinical ver-
tebral fracture, and morphometric vertebral fracture, with re-
ductions in the other fracture outcomes fell short of statistical
significance.
Treatment interaction
There was no significant interaction between any of the vari-
ables and time. There was a significant interaction between
romosozumab antifracture efficacy and the outcomes of any
clinical fracture, osteoporotic fracture, and MOF (Table 3) as
shown by a decrease in HRs (i.e. greater efficacy) with in-
creasing fracture probability at baseline. For example, the re-
duction in any clinical fracture was 19% with the 95% CIs
embracing unity at the 10th percentile (FRAX® MOF proba-
bility 3.7%), whereas at the 50th percentile (FRAX® MOF
probability 7.4%), the reduction was 29% (95% CI 3–49%)
(Table 3). At the 90th percentile (FRAX® MOF probability
18.9%), the reduction was 54%. The effects of romosozumab
for the three categories of fracture outcomes are shown as a
continuous function in Fig. 1. For each, there was greater
efficacy at higher baseline probabilities. In the case of any
clinical fracture, treatment with romosozumab was associated
with a significant reduction in fracture risk with probabilities
of 7% or more. For the outcome of osteoporotic fracture and
MOF, significant effects of treatment were observed with
probabilities of 9% or more and 12% or more, respectively.
The interactions were no longer significant (p = 0.11–0.21) for
these outcomes when FRAX® was calculated with bone min-
eral density (BMD) (data not shown), but the trend was very
similar in that higher fracture probabilities were associated
with greater efficacy.
In contrast to the interaction between baseline probability
and fracture outcomes that were largely composed of fractures
at nonvertebral sites, the HRs were stable across the range of
baseline FRAX® probabilities for vertebral fracture, both mor-
phometric and clinical fracture (Table 3), consistent with sim-
ilar treatment efficacy regardless of baseline risk. As expected,
when clinical vertebral fractures were excluded from the out-
comes of any clinical fracture, osteoporotic fracture, and
MOF, the significance of the interactions between
romosozumab efficacy and baseline fracture probabilities be-
came even more marked (p = 0.046, p = 0.046, and p = 0.039,
respectively). This is illustrated for osteoporotic fractures
without vertebral fractures (i.e. nonvertebral fractures) in
Table 3 and Fig. 1. Given the relatively small number of
incident hip fractures in the first year of FRAME, no signifi-
cant interaction was seen for this outcome, though a similar
trend was observed to that at overall nonvertebral sites.
In the additional analyses looking at potential interaction
between romosozumab efficacy and individual risk factors,
there were no statistically significant interactions with the con-
tinuous (age, BMI) or categorical (smoking, prior fracture, and
parental history) baseline variables. An exception was an un-
expected interaction between baseline femoral neck BMD and
efficacy (p = 0.097) in the sense that the lower the T-score, the
less the effect. The differences in efficacy at different T-scores
were, however, modest. For example, at a T-score of − 2.99
the HR for clinical fractures was 0.54 (95% CI 0.38–0.76). At
a T-score of − 2.62, the HR was 0.41 (95% CI 0.28–0.59).
Regional variation
The baseline median fracture probabilities were lower in the
Latin American centres compared with other regions for MOF
(5.0% vs. 10.0%, respectively, calculated without BMD) and
hip fracture (1.9% vs. 3.2%, respectively). The result of the
interaction analysis for the outcome of any clinical fracture,
confined to the Latin American centres, is shown
superimposed on the overall study analysis in Fig. 2. The data
from the Latin American countries showed a similar
Table 2 Effects of romosozumab
compared to placebo over 12
months according to the fracture
outcome. The current analysis
used a Poisson model adjusting
for age and time since baseline
Treatment effect (HR, 95% CI) Two-sided p value
Any fracture 0.63 (0.47, 0.85) 0.003
Osteoporotic fracture 0.66 (0.46, 0.93) 0.018
Major osteoporotic fracture 0.68 (0.44, 1.03) 0.071
Hip fractures 0.47 (0.19, 1.14) 0.096
Nonvertebral fracture 0.72 (0.50, 1.03) 0.071
Clinical vertebral fracture 0.20 (0.04, 0.91) 0.038
Morphometric vertebral fracture 0.27 (0.16, 0.47) < 0.001
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qualitative relationship between efficacy and FRAX®, though
this fell short of statistical significance (p > 0.30) with wide
confidence limits. Similar findings were observed for the out-
come of osteoporotic fracture (data not shown).
Discussion
The aim of this analysis was to determine the interaction, if
any, between baseline fracture probability and the efficacy of
romosozumab to allow comparison with similar analyses from
placebo-controlled trials of other osteoporosis treatments. The
design of the phase 3 trials of romosozumab posed challenges
to fulfil this aim in that only the first placebo-controlled year
of the FRAME study provided the opportunity for such an
assessment. The category of “any clinical fracture” (which
included fractures of the hand, feet, face, and skull) was added
in this analysis to ensure that the power of the study was
optimised by accounting for all fractures occurring within that
1-year period. While this study’s approach to the analysis was
not identical to that used in the original publications of the
FRAME trial, it is important to note that this study’s results
on overall fracture risk reductions in the first year were very
comparable to those reported previously [3, 23]. Importantly,
the present analysis also demonstrates significant interactions
between efficacy and baseline FRAX fracture probability,
Table 3 Hazard ratio between treatments (romosozumab versus placebo) in the first year of FRAME for various fracture outcomes at different values













10th 3.65 0.81 (0.55–1.20) 0.88 (0.56–1.40) 0.96 (0.55–1.68) 1.00 (0.62–1.61) 0.25 (0.12–0.52) 0.14 (0.02–1.10)
25th 4.70 0.78 (0.54–1.13) 0.84 (0.55–1.30) 0.91 (0.54–1.54) 0.95 (0.61–1.49) 0.26 (0.13–0.51) 0.15 (0.02–1.04)
50th 7.38 0.71 (0.51–0.97) 0.76 (0.52–1.10) 0.80 (0.51–1.27) 0.84 (0.57–1.24) 0.26 (0.14–0.48) 0.17 (0.03–0.93)
75th 12.23 0.59 (0.43–0.81) 0.62 (0.43–0.89) 0.64 (0.41–0.99) 0.67 (0.46–0.98) 0.27 (0.16–0.47) 0.21 (0.04–0.98)
90th 18.88 0.46 (0.29–0.73) 0.47 (0.28–0.79) 0.47 (0.25–0.87) 0.49 (0.29–0.84) 0.29 (0.16–0.52) 0.29 (0.04–1.93)
p value for
interaction*
0.06 0.07 0.08 0.046 > 0.30 > 0.30
*Two-sided p value for interaction between treatment and FRAX®


































































Probability of a major osteoporoc fracture (%)
p=0.046Non-vertebral fracture
Fig. 1 Effect of romosozumab on any clinical fracture (top left panel),
osteoporotic fracture (top right panel), MOF (lower left panel), and
nonvertebral fracture (osteoporotic fractures excluding vertebral
fractures) (lower right panel) compared with placebo expressed as HR
with 95%CIs across the range ofMOF probabilities at baseline calculated
without BMD
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calculated without BMD. Hazard ratios decreased (i.e. greater
efficacy) with increasing fracture probability for any clinical
fracture, osteoporotic fracture, and MOF, suggesting that the
benefits of romosozumab will be most marked in patients at
high risk of fracture. Notably, a similar pattern was observed
when BMD was included in the calculation of FRAX® prob-
abilities, though this did not reach statistical significance. The
reasons for this are not clear, but as reported, we observed an
unexpected relationship between femoral neck BMD with
lower romosozumab efficacy at lower BMD. It is possible that
the relationship between the risk of fracture and BMDwas not
as expected, given that low BMD was an inclusion criterion
for the trial but associated risk factors such as prior hip and
moderate/severe vertebral fractures were exclusion criteria,
and this may have introduced confounding. In addition, the
inclusion of patients with low BMD from countries with low
risk of fracture might also have contributed to this
observation.
The observation that the interaction is only observed for
nonvertebral fractures, and not for vertebral fractures, appears
to be a novel finding. It has been appreciated for many years
that the responsiveness to osteoporosis treatments varies be-
tween vertebral and nonvertebral sites; certainly, the size and
speed of onset of effect of treatment have frequently been
observed as greater for vertebral than nonvertebral fracture.
In the current study, the majority of analyses of the effects
of treatment-induced reductions in vertebral fractures across
the range of baseline FRAX® probability revealed no signifi-
cant interactions; the similar and stable efficacy suggests a
floor/ceiling effect for each drug on vertebral fracture out-
comes. For example, in the setting of anabolic therapy,
teriparatide administered daily or weekly has shown
reductions in vertebral fractures of 66–79% without any inter-
action with baseline fracture risk [14, 15]. The interaction with
baseline probability for nonvertebral fractures seen with
romosozumab raises questions about the mechanism of frac-
ture reductions in the setting of increased fracture risk.
Several studies have examined the interaction between
FRAX®-based probabilities with effectiveness in placebo-
controlled studies, including treatment with raloxifene [10],
bazedoxifene [8], clodronate [9], denosumab [13],
alendronate [12], daily and weekly teriparatide [14, 15], and
abaloparatide [16]. Several of these studies have shown great-
er efficacy against fracture in individuals at higher risk when
treated with clodronate, bazedoxifene, or denosumab—
romosozumab can now be added. This FRAX® dependency
has marked consequences for health economic analysis, illus-
trated when comparing the cost-effectiveness of the two se-
lective oestrogen receptor modulators, raloxifene and
bazedoxifene [24]. The appreciation of greater efficacy at
higher baseline risks, as seen with bazedoxifene, can alter
conclusions drawn about cost-effectiveness, with more expen-
sive but more effective agents potentially preferred in those at
highest risk of fracture. Superior and more rapid antifracture
efficacy has now been shown for anabolic treatments in head-
to-head trials with antiresorptive agents, including teriparatide
compared with risedronate [25] and romosozumab compared
with alendronate [4]. This knowledge is starting to influence
clinical guidelines and approaches to management, where
there is increasing recognition that anabolic agents might be
seen as first-line agents in patients at very high risk of fracture,
especially where the risk might be particularly high in the
short term, for example after a recent osteoporotic fracture
[26, 27].
Fig. 2 Effect of romosozumab on
any clinical fracture compared
with placebo expressed as the HR
with 95% CIs across the range of
MOF probabilities (1st to 99th
percentile) at baseline calculated
without BMD. Dotted lines are
derived from the first year of the
FRAME study. Solid lines depict
the first-year data from the Latin
American countries
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These findings are helpful in explaining apparent regional
differences in the efficacy of romosozumab on nonvertebral
fracture [3]. The FRAME study reported that romosozumab
did not significantly decrease the incidence of nonvertebral
fractures in the first year (HR = 0.75; 95% CI 0.53–1.05) with
a similar effect size at the end of the second year, when both
groups had received denosumab for a year. A subsequent post
hoc analysis showed that the effect of romosozumab on
nonvertebral fractures differed between the Latin American
region (HR = 1.25; 95% CI 0.68–2.27) and other regions
(HR = 0.58; 95% CI 0.37–0.89) [3, 7]. The present findings
indicate that apparent regional differences in efficacy are like-
ly related to differences in fracture probability rather than to
ethnicities or other reasons. This view is supported by the
observation in the present analysis that high-risk patients in
Latin America appear to respond to treatment in much the
same way as in the FRAME cohort in general. A caveat is that
the interaction term between efficacy and FRAX® was not
significant in the analysis confined to women from Latin
America, but this is limited by the low number of events in
this population.
This analysis has a number of strengths and limitations.
Subgroup analyses, especially those undertaken post hoc, re-
duce the statistical power of studies and increase the risk of
type 1 errors [28]. Examining for interactions using a contin-
uous risk variable, such as baseline fracture probability, re-
duces the erroneous impact of categorical subgroup analyses.
For example, in a post hoc analysis of romosozumab efficacy
on nonvertebral fracture risk using an intervention threshold in
keeping with US treatment thresholds (FRAX® 10-year prob-
ability of major osteoporotic fracture ≥ 20% or hip fracture ≥
3%) suggested that romosozumab was ineffective below this
threshold [7]. The current analysis suggests that efficacy of
romosozumab can be observed at substantially lower
thresholds, for example at MOF probabilities of 9–
12% for the outcomes of osteoporotic or major osteopo-
rotic fractures. The present analysis is confined to a
total treatment exposure of just 1 year, a substantially
shorter duration than in other placebo-controlled studies
in osteoporosis. Nonetheless, the rapid efficacy of
romosozumab on vertebral and clinical fracture out-
comes delivers an efficacy that can then be examined
for interactions.
In conclusion, there are significant interactions between
baseline fracture probability and the effect of romosozumab
on clinical fracture, osteoporotic fracture, and MOF when
compared with placebo in the first year of the FRAME study.
Furthermore, the evidence supports the view that high-risk
patients in Latin America appear to respond to treatment in
much the same way as in the FRAME cohort in general. The
increased efficacy of romosozumab at higher levels of base-
line risk should be taken into account in health economic
analyses.
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